Overview

Efficacy of Acarbose on Intestinal Microbiome and Incretins of Type 2 Diabetes

Status:
Unknown status
Trial end date:
2014-06-01
Target enrollment:
0
Participant gender:
All
Summary
This study is aimed to investigate the effect of acarbose on intestinal microbiome and incretins, therefore to explore the new pathways or new targets to treat type 2 diabetes.
Phase:
Phase 4
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Shanghai Jiao Tong University School of Medicine
Treatments:
Acarbose
Glipizide
Incretins
Criteria
Inclusion Criteria:

- Newly diagnosed Type 2 Diabetes, without any previous drug treatment,

- 7.0 mmol/l <=FBG<=13.O mmol/l, HbA1C <=10%

- Body mass index (BMI) < 35kg/m2 (inclusive);

- Understand and voluntarily sign an informed consent document prior to any study
related assessments/procedures are conducted

- Having good study compliance

Exclusion Criteria:

- Intestinal surgery or recent abdominal surgery within 1 year

- Taken immunosuppressive agents, steroid,antidiarrhea agents, antibiotics and other
gastrointestinal motility agents within 3 months

- Severe liver dysfunction, including serum alanine aminotransferase concentration more
than 2.5 times above upper limit of normal range, abnormal renal function (GFR <
60ml/min)

- Other severe conditions which will put the patients in high risk during the study

- Any clinically significant allergic disease

- Women in pregnancy or under breast feeding